Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Early data on venetoclax-containing regimens for the treatment of chronic lymphocytic leukemia (CLL) show promising results with deep remissions, but are hampered by potential risk for tumor lysis syndrome (TLS). Whether optimal duration of venetoclax treatment can be guided by minimal residual dise...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Kater, Arnon P., Kersting, Sabina, van Norden, Yvette, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H., Evers, Ludo M., Croon-de Boer, Fransien, Schreurs, John, van der Spek, Ellen, Visser, Hein, Idink, Cecile, Wittebol, Shulamiet, Hoogendoorn, Mels, Tonino, Sanne H., Mobasher, Mehrdad, Levin, Mark-David
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2018
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6306887/
https://ncbi.nlm.nih.gov/pubmed/30552161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019422
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi